Treatment of individuals with severe sickle cell disease with OTQ923, an autologous, ex vivo, CRISPR/Cas9-edited, CD34+ hematopoietic stem and progenitor cell product, leads to durable engraftment and fetal hemoglobin induction Meeting Abstract


Authors: Sharma, A.; Boelens, J. J.; Cancio, M. I.; Hankins, J.; Bhad, P. A.; Lewandowski, A.; Zhao, X.; Chitnis, S.; Peddinti, R.; Zheng, Y.; Kapoor, N.; Ciceri, F.; Yuan, J.; Yu, V. W.; Stevenson, S. C.; De Vita, S.; LaBelle, J.
Abstract Title: Treatment of individuals with severe sickle cell disease with OTQ923, an autologous, ex vivo, CRISPR/Cas9-edited, CD34+ hematopoietic stem and progenitor cell product, leads to durable engraftment and fetal hemoglobin induction
Meeting Title: 64th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 140
Issue: Suppl. 1
Meeting Dates: 2022 Dec 10-13
Meeting Location: New Orleans, LA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2022-11-15
Start Page: 1906
End Page: 1908
Language: English
ACCESSION: WOS:000893223201372
DOI: 10.1182/blood-2022-166254
PROVIDER: wos
Notes: Meeting Abstract -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Maria   Cancio
    59 Cancio
  2. Jaap Jan Boelens
    215 Boelens